Annuloplasty System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Mitral Valve Repair, Tricuspid Valve Repair, Aortic Valve Repair), By End Use (Hospitals, Ambulatory Surgical Centers and Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 489.21 MIllion
CAGR (2026-2031)	5.79%
Fastest Growing Segment	Mitral Valve Repair
Largest Market	North America
Market Size (2031)	USD 685.75 MIllion

Market Overview

The Global Annuloplasty System Market will grow from USD 489.21 MIllion in 2025 to USD 685.75 MIllion by 2031 at a 5.79% CAGR. Annuloplasty systems are implantable prosthetic devices utilized in cardiac surgery to reconstruct and reshape the heart valve annulus, thereby restoring proper valve function and preventing regurgitation. The market trajectory is heavily influenced by the rising global geriatric population and the concurrent increase in valvular heart conditions requiring surgical intervention. Additionally, the clinical consensus favoring valve repair over replacement to avoid lifelong anticoagulation therapy acts as a primary catalyst for industry growth. According to the American Heart Association, in 2024, the global prevalence of nonrheumatic degenerative mitral valve disease was reported to be approximately 15.5 million cases, underscoring the substantial demand for effective repair solutions.

A significant impediment to broader market adoption involves the high level of surgical expertise required to perform effective annuloplasty procedures. The technical complexity mandates extensive surgeon training and experience, which restricts the availability of these advanced repair options to specialized high-volume centers and limits accessibility in developing healthcare regions.

Key Market Drivers

The rising prevalence of mitral and tricuspid valve regurgitation, particularly among the aging demographic, serves as a primary engine for market expansion. As the global geriatric population expands, the incidence of degenerative valvular pathologies increases, necessitating effective repair interventions to manage symptoms and prevent heart failure. This demographic shift creates a sustained demand for annuloplasty systems designed to restore native valve geometry. According to AHA Journals, November 2025, in the 'Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults' study, the estimated prevalence of moderate to severe tricuspid regurgitation in the general population is 3%, a figure that significantly rises with age.

Technological advancements in minimally invasive and transcatheter annuloplasty systems are fundamentally reshaping the treatment landscape by offering viable alternatives to open-heart surgery. Innovations in catheter-based delivery systems allow for precise implant positioning in high-risk patients, thereby expanding the addressable patient pool and accelerating adoption rates in developed markets. This surge in innovation is reflected in the financial performance of key industry players. According to Abbott, January 2025, in the 'Fourth Quarter 2024 Financial Results', Structural Heart unit sales increased by 17% for the full year 2024, reaching $2.25 billion, largely driven by the adoption of new repair technologies. Furthermore, the rapid uptake of these advanced therapies is evident across the sector; according to Edwards Lifesciences, in 2025, sales for their Transcatheter Mitral and Tricuspid Therapies division grew 88% in the fourth quarter of 2024 to $105 million.

Download Free Sample Report

Key Market Challenges

The high level of specialized surgical expertise required to perform annuloplasty procedures stands as a substantial barrier hindering the growth of the Global Annuloplasty System Market. Valve repair is technically more demanding than valve replacement, necessitating that surgeons possess advanced skills to precisely reconstruct the annulus and restore physiological function. This steep learning curve limits the number of qualified operators, resulting in a concentration of these procedures solely in high-volume, specialized medical centers. Consequently, many hospitals, particularly in emerging markets or lower-volume facilities, default to valve replacement surgeries simply because they lack the requisite personnel to perform complex repairs, thereby stifling the adoption of annuloplasty devices.

This workforce constraint creates a significant bottleneck that prevents the market from meeting the rising prevalence of valvular disease. The inability to scale the surgical workforce at the same pace as patient demand directly caps the procedural volume for annuloplasty systems. According to the Association of American Medical Colleges, in 2024, projections indicated a shortage of between 10,100 and 19,900 physicians in surgical specialties by 2036. This widening gap between the availability of highly trained surgeons and the clinical need for intervention limits market expansion, as the industry cannot deploy its technologies effectively without a sufficient base of capable users.

Key Market Trends

The increased utilization of robotic-assisted valve repair platforms is significantly influencing market dynamics by overcoming the visualization and dexterity limitations associated with conventional minimally invasive surgery. These systems enable surgeons to perform complex annuloplasty procedures with high precision through small incisions, effectively bridging the gap between open-heart efficacy and less invasive approaches. The expanding footprint of these advanced surgical modalities is evident in adoption metrics. According to Intuitive Surgical, January 2025, in the 'Fourth Quarter 2024 Financial Results', worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023, reflecting the rapid integration of robotic technologies into general and cardiac surgical practice.

Concurrently, the integration of 3D printing for patient-specific device customization and pre-surgical planning is becoming a critical component of the annuloplasty workflow. By generating anatomically accurate models from patient imaging, clinicians can optimize ring sizing and simulate implant placement prior to the operation, thereby reducing intraoperative errors and improving long-term repair durability. This shift toward personalized medical manufacturing is driving substantial growth in the supporting ecosystem. According to Materialise, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', revenues from the company’s Medical segment grew by 14.8% for the full year 2024, underscoring the rising demand for additive manufacturing solutions in complex clinical interventions.

Segmental Insights

The Mitral Valve Repair segment is identified as the fastest-growing area within the global annuloplasty system market. This rapid expansion is primarily driven by the rising prevalence of mitral valve regurgitation, which necessitates effective clinical intervention to prevent heart failure. Additionally, there is a strong clinical preference for valve repair over replacement due to associated improvements in long-term survival and the preservation of native heart function. Continued product approvals by regulatory bodies like the U.S. FDA for repair devices further support this growth, encouraging wider adoption among healthcare providers prioritizing patient safety.

Regional Insights

North America maintains a dominant position in the Global Annuloplasty System Market, primarily driven by the high prevalence of mitral and tricuspid valve regurgitation requiring surgical repair. The region benefits from a robust healthcare infrastructure that facilitates early diagnosis and the adoption of effective treatment technologies. Market expansion is further supported by favorable reimbursement policies established by the Centers for Medicare & Medicaid Services, which improve patient access to necessary procedures. Additionally, clear regulatory frameworks provided by the U.S. Food and Drug Administration foster a stable environment for product approval and clinical adoption.

Recent Developments

• In June 2025, Ancora Heart, Inc. announced that it had reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System. This investigational device, designed to treat patients with heart failure and reduced ejection fraction, functions by cinching the left ventricular wall to reduce its size and stress, thereby addressing functional mitral regurgitation. The six-month follow-up data from the initial cohort of 250 patients is intended to support the company's Premarket Approval submission to the U.S. Food and Drug Administration.
• In March 2025, Valcare Medical Inc. announced that the U.S. Food and Drug Administration had granted approval for the AMEND Trans-Septal System to commence an Early Feasibility Study under an investigational device exemption. The AMEND system is a transcatheter mitral valve repair device featuring a semi-rigid, closed, D-shaped annuloplasty ring designed to replicate the efficacy of the surgical standard for treating mitral insufficiency. This study will evaluate the safety and functionality of the device in patients with symptomatic moderate-to-severe functional mitral regurgitation across several investigational centers in the United States.
• In March 2025, Cardiac Dimensions announced the closing of an oversubscribed $53 million Series E financing round led by Ally Bridge Group, with participation from new and existing investors. The funding was secured to support the completion of the U.S. pivotal EMPOWER Trial and to accelerate the global commercial expansion of the Carillon Mitral Contour System. The Carillon device is a minimally invasive transcatheter annuloplasty system designed to treat functional mitral regurgitation in heart failure patients by reshaping the mitral annulus from the coronary sinus.
• In June 2024, Corcym announced a strategic partnership with Sunflowers Medtech to foster deep cooperation in the field of cardiac surgery in China. This collaboration aims to leverage complementary strengths in innovation, professional training, and clinical application to advance the development and distribution of surgical solutions for structural heart disease. The alliance focuses on benefiting patients by combining Corcym’s global expertise in heart valve products, such as its annuloplasty rings, with Sunflowers Medtech’s local commercial network and industry experience.

Key Market Players

• Medtronic Plc
• Abbott Laboratories, Inc.
• Edwards Lifesciences Corporation
• Corcym Group
• Labcor Laboratórios Ltda
• Affluent Medical SA
• Valcare Medical
• Braile Biomédica
• LivaNova PLC
• Micro Interventional Devices, Incorporated

By Application	By End Use	By Region
Mitral Valve Repair Tricuspid Valve Repair Aortic Valve Repair	Hospitals Ambulatory Surgical Centers and Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Annuloplasty System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Annuloplasty System Market, By Application:

• Mitral Valve Repair
• Tricuspid Valve Repair
• Aortic Valve Repair

• Annuloplasty System Market, By End Use:

• Hospitals
• Ambulatory Surgical Centers and Others

• Annuloplasty System Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE